Publication

Hepatocyte mARC1 promotes fatty liver disease

JHEP Reports 5(5):100693, 2023 Lewis LC, Chen L, Hameed LS, Kitchen RR, Maroteau C, Nagarajan SR, Norlin J, Daly CE, Szczerbinska I, Hjuler ST, Patel R, Livingstone EJ, Durrant TN, Wondimu E, BasuRay S, Chandran A, Lee WH, Hu S, Gilboa B, Grandi ME, Toledo EM, Erikat AHA, Hodson L, Haynes WG, Pursell NP, Coppieters K, Fleckner J, Howson JMM, Andersen B, Ruby MA

Subjects

GAN DIO-NASH (GAN DIO-MASH) mouse Mouse Non-alcoholic steatohepatitis/Metabolic dysfunction-associated steatohepatitis (NASH/MASH)mARC1 siRNA

Share this page

Resource Library

Related resources

Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients

Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis

Disease progression in the non-obese CDAA-HFD mouse model of advanced NASH and fibrosis

Metabolic, biochemical, histological, and transcriptomic effects of Firsocostat in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH 

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650